With a new CEO and $12.5M in its pocket, UNC spinout sets sights on human drug trials
A drug development company that spun out of UNC-Chapel Hill brought on a CEO and now set its sights See all stories on this topic
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Comments